Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· December 6, 2025

Is It Better to Collect Social Security at 62, 67, or 70? A Broad-Based Statistical Analysis Provides a Decisive Answer.

View original at nasdaq.com
Is It Better to Collect Social Security at 62, 67, or 70? A Broad-Based Statistical Analysis Provides a Decisive Answer. Key Points The Social Security Administration uses four straightforward variables to calculate your monthly Social Security benefit…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • One easy trick could pay you as much as $23,760 more each year in Social Security benefits

    80% confidence
  • Retired workers could see their payouts reduced by up to 23% in 2033

    80% confidence
  • 80% to 90% of Social Security beneficiaries need their payout in some capacity to make ends meet

    80% confidence
  • 57% of the 20,000 claims studied would have been optimal at age 70

    80% confidence
  • Around 10% of claims at age 67 would have been optimal

    80% confidence
  • Only 4% of the 20,000 retired-worker claims analyzed were optimal

    80% confidence
  • 79% of the 20,000 retired-worker claims examined had an initial collection age ranging from 62 through 64, but only 8% of optimal claims occurred at these three claiming ages combined

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com